Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - alirocumab 75 mg/ml;   - solution for injection - 75 mg/ml - active: alirocumab 75 mg/ml   excipient: histidine polysorbate 20 sucrose water for injection - primary hypercholesterolaemia praluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 75 mg - granules - excipient ingredients: hypromellose acetate succinate; sodium lauryl sulfate; lactose monohydrate; mannitol; sucralose; croscarmellose sodium; silicon dioxide; magnesium stearate - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data(see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 50 mg - granules - excipient ingredients: hypromellose acetate succinate; sodium lauryl sulfate; lactose monohydrate; mannitol; sucralose; croscarmellose sodium; silicon dioxide; magnesium stearate - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data(see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - tirofiban hydrochloride, quantity: 14.05 mg (equivalent: tirofiban, qty 12.5 mg) - injection, concentrated - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid; dibasic sodium phosphate dihydrate; water for injections - tirofiban juno, in combination with heparin, is indicated for patients with unstable angina or non-q-wave myocardial infarction to prevent cardiac ischaemic events. (see pharmacology and dosage and administration.)

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 150 mg - tablet, film coated - excipient ingredients: carnauba wax; croscarmellose sodium; silicon dioxide; magnesium stearate; microcrystalline cellulose; sodium lauryl sulfate; hypromellose acetate succinate; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data(see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties)

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 150 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; silicon dioxide; carnauba wax; sodium lauryl sulfate; hypromellose acetate succinate; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data(see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties)

Amerika Serikat - Inggris - NLM (National Library of Medicine)

edwards pharmaceuticals, inc. - guaifenesin (unii: 495w7451vq) (guaifenesin - unii:495w7451vq), phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv) - guaifenesin 100 mg in 5 ml - temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other respiratory allergies: - runny nose - sneezing - itching of the nose or throat - itchy, watery eyes - nasal congestion - reduces swelling of nasal passages - helps loosen phlegm (mucus) and thin bronchial secretions to drain bronchial tubes and make coughs more productive

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hypromellose; microcrystalline cellulose; propylene glycol; magnesium stearate; titanium dioxide; lactose monohydrate; sunset yellow fcf aluminium lake; sodium lauryl sulfate; purified talc; maize starch - treatment of schizophrenia and related psychoses. . short term treatment of acute mania associated with bipolar 1 disorder. . treatment of behavioural disturbances in dementia. . treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. . treatment of behavioural disorders associated with autism in children and adolescents.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; maize starch; microcrystalline cellulose; hypromellose; purified talc; propylene glycol; sodium lauryl sulfate; iron oxide red; magnesium stearate; colloidal anhydrous silica; lactose monohydrate - treatment of schizophrenia and related psychoses. . short term treatment of acute mania associated with bipolar 1 disorder. . treatment of behavioural disturbances in dementia. . treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. . treatment of behavioural disorders associated with autism in children and adolescents.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; magnesium stearate; hypromellose; maize starch; microcrystalline cellulose; propylene glycol; lactose monohydrate; purified talc; colloidal anhydrous silica - treatment of schizophrenia and related psychoses. . short term treatment of acute mania associated with bipolar 1 disorder. . treatment of behavioural disturbances in dementia. . treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. . treatment of behavioural disorders associated with autism in children and adolescents.